Adma Biologics (ADMA) Amortizatization of Intangibles (2011 - 2026)
Adma Biologics' (ADMA) quarterly Amortizatization of Intangibles came in at $197000.0 in Q4 2025, down 10.05% YoY from $219000.0 in Q4 2024, and up 15.88% on a QoQ basis from $170000.0 in Q3 2025.
Powered by 
Analysis
Adma Biologics (ADMA) Amortizatization of Intangibles (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Amortizatization of Intangibles data on file, last reported at $197000.0 in Q4 2025.
- Quarterly Amortizatization of Intangibles fell 10.05% year-over-year to $197000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $717000.0 (down 24.61% YoY) and the FY2025 annual result came in at $717000.0, down 24.61% from the prior year.
- Amortizatization of Intangibles improved to $197000.0 in Q4 2025, from $170000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $981066.0 in Q3 2022 to a low of $160000.0 in Q2 2025.
- A 5-year average of $428050.0 and a median of $454075.5 in 2021 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles soared 101.87% — and 2024, when it sank 68.62%.
- Tracing ADMA's Amortizatization of Intangibles over 5 years: stood at $502858.0 in 2021, then retreated by 1.79% to $493873.0 in 2022, then soared by 41.33% to $698000.0 in 2023, then slumped by 68.62% to $219000.0 in 2024, then dropped by 10.05% to $197000.0 in 2025.
- The last three Amortizatization of Intangibles figures came in at $197000.0 (Q4 2025), $170000.0 (Q3 2025), and $160000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 678,000.00 |
| 10 | Adma Biologics | 2.18 Bn | 2.04 Bn | 86.28 Mn | 192,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 192,000.00 |
| Mar 31, 2026 | 191,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 227,000.00 |
| Mar 31, 2024 | 253,000.00 |
| Dec 31, 2023 | 698,000.00 |
| Sep 30, 2023 | 721,000.00 |
| Jun 30, 2023 | 687,000.00 |
| Mar 31, 2023 | 488,000.00 |
| Dec 31, 2022 | 493,873.00 |
| Sep 30, 2022 | 981,066.00 |
| Jun 30, 2022 | 342,219.00 |
| Mar 31, 2022 | 584,842.00 |
| Dec 31, 2021 | 502,858.00 |
| Sep 30, 2021 | 485,991.00 |